TY - JOUR
T1 - Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels
AU - Molinari, Ana J.
AU - Thorp, Silvia I.
AU - Portu, Agustina M.
AU - Saint Martin, Gisela
AU - Pozzi, Emiliano C.C.
AU - Heber, Elisa M.
AU - Bortolussi, Silva
AU - Itoiz, Maria E.
AU - Aromando, Romina F.
AU - Monti Hughes, Andrea
AU - Garabalino, Marcela A.
AU - Altieri, Saverio
AU - Trivillin, Verónica A.
AU - Schwint, Amanda E.
N1 - Funding Information:
The authors gratefully acknowledge the expert advice of Dr. luis otegui and the major statistical support provided by Dr. Gustavo Santa Cruz. The authors also acknowledge the generous gift of thalidomide by Triquim S.A. and laboratorio lazar (Argentina) and the expert support of Dr. Claudio Devida and his team with iCP-MS boron measurements. This study was supported in part by a grant from the National Agency for the Promotion of Science and Technology (ANPCyT) and a grant from the National Research Council (CoNiCET) of Argentina.
Publisher Copyright:
© 2015 Informa Healthcare.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Background. We previously demonstrated the therapeutic success of sequential boron neutron capture therapy (Seq-BNCT) in the hamster cheek pouch oral cancer model. It consists of BPA-BNCT followed by GB-10-BNCT 24 or 48 hours later. Additionally, we proved that tumor blood vessel normalization with thalidomide prior to BPA-BNCT improves tumor control. The aim of the present study was to evaluate the therapeutic efficacy and explore potential boron microdistribution changes in Seq-BNCT preceded by tumor blood vessel normalization. Material and Methods. Tumor bearing animals were treated with thalidomide for tumor blood vessel normalization, followed by Seq-BNCT (Th+ Seq-BNCT) or Seq-Beam Only (Th+ Seq-BO) in the window of normalization. Boron microdistribution was assessed by neutron autoradiography. Results. Th+ Seq-BNCT induced overall tumor response of 100%, with 87 (4)% complete tumor response. No cases of severe mucositis in dose-limiting precancerous tissue were observed. Differences in boron homogeneity between tumors pre-treated and not pre-treated with thalidomide were observed. Conclusion. Th+ Seq-BNCT achieved, for the first time, response in all treated tumors. Increased homogeneity in tumor boron microdistribution is associated to an improvement in tumor control.
AB - Background. We previously demonstrated the therapeutic success of sequential boron neutron capture therapy (Seq-BNCT) in the hamster cheek pouch oral cancer model. It consists of BPA-BNCT followed by GB-10-BNCT 24 or 48 hours later. Additionally, we proved that tumor blood vessel normalization with thalidomide prior to BPA-BNCT improves tumor control. The aim of the present study was to evaluate the therapeutic efficacy and explore potential boron microdistribution changes in Seq-BNCT preceded by tumor blood vessel normalization. Material and Methods. Tumor bearing animals were treated with thalidomide for tumor blood vessel normalization, followed by Seq-BNCT (Th+ Seq-BNCT) or Seq-Beam Only (Th+ Seq-BO) in the window of normalization. Boron microdistribution was assessed by neutron autoradiography. Results. Th+ Seq-BNCT induced overall tumor response of 100%, with 87 (4)% complete tumor response. No cases of severe mucositis in dose-limiting precancerous tissue were observed. Differences in boron homogeneity between tumors pre-treated and not pre-treated with thalidomide were observed. Conclusion. Th+ Seq-BNCT achieved, for the first time, response in all treated tumors. Increased homogeneity in tumor boron microdistribution is associated to an improvement in tumor control.
UR - http://www.scopus.com/inward/record.url?scp=84919628776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919628776&partnerID=8YFLogxK
U2 - 10.3109/0284186X.2014.925140
DO - 10.3109/0284186X.2014.925140
M3 - Article
C2 - 24960584
AN - SCOPUS:84919628776
SN - 0284-186X
VL - 54
SP - 99
EP - 106
JO - Acta Oncologica
JF - Acta Oncologica
IS - 1
ER -
